THE CELL HOLDS THE ANSWERS,
AND OUR TESTS UNLOCK THOSE ANSWERS TO EXTEND LIVES.
AR-V7 TEST
The AR-V7 test is the first and only CTC-based liquid-biopsy test that is Medicare reimbursed and clinically-validated for men with metastatic castration-resistant prostate cancer (mCRPC). Requiring only a simple, non-invasive blood draw, this groundbreaking test empowers patients, with their doctors, the confidence to choose the most effective precision therapies.
![arv7](https://www.epicsciences.com/wp-content/uploads/2019/04/arv7.jpg)
BIOPHARMA SOLUTIONS
For pharmaceutical and clinical investigation partners, our program delivers a bias-free approach for cancer research, to develop clinical solutions that enhance drug development and provide valuable insights into the dynamics of cancer growth and evolution.
0
CANCER TYPES
0
ACADEMIC PARTNERS
0
PHARMACEUTICAL PARTNERS
>
0
PUBLICATIONS
>
0
CLINICAL TRIALS
>
0
SINGLE CTC GENOMES SEQUENCED
>
0
PATIENT SAMPLES CONTRACTED